Key takeaways:
- The assembly will happen June 21 in Las Vegas.
- Attendees will discover subjects resembling regulatory concerns for pivotal trial design and AI in imaging and scientific growth.
Scientific Trials on the Summit will probably be held Saturday, June 21, at Fontainebleau Las Vegas.
The assembly will give attention to the most recent information in vitreoretinal care from ongoing scientific trials. Via an emphasis on relationship constructing, the assembly will discover methods to design and execute efficient scientific trials.
Healio spoke with Arshad M. Khanani, MD, MA, FASRS, founder and co-chair of Scientific Trials on the Summit (CTS), in regards to the assembly’s development since its debut in 2021 and the important thing subjects that will probably be of curiosity to retina specialists from world wide.
Healio: Because the founding father of CTS, what did you hope to perform with this assembly?
Khanani: CTS was established to convey collectively all key stakeholders concerned in drug growth, together with retina specialists, sponsors, contract analysis organizations, scientific websites and buyers, with the objective of designing and executing trials extra effectively to ship new remedy choices to sufferers sooner.
Healio: How has the assembly grown through the years?
Khanani: Since its inception in 2021, CTS has skilled exponential development and is now acknowledged as one of the vital vital conferences centered on scientific trials in retina.
In earlier years, CTS was solely invite just for college. This 12 months, now we have opened a devoted observe for invited non-faculty retina specialists to attend. This enables extra clinicians to interact with the most recent developments and construct significant connections with main stakeholders within the discipline.
Healio: What scorching subjects will probably be on the forefront of the assembly this 12 months?
Khanani: A serious spotlight would be the unveiling of first-time scientific trial outcomes from important 2025 information readouts, providing helpful insights into the way forward for retina therapeutics.
Moreover, this system will function a spread of informative periods protecting subjects resembling the applying of AI in imaging and scientific growth, regulatory concerns for pivotal trial design, the promise of gene remedy and tyrosine kinase inhibitors in treating retinal vascular illnesses, and the position of imaging endpoints in geographic atrophy trials.
Healio: Outdoors of the periods, are there any particular occasions that attendees can sit up for?
Khanani: As an invite-only assembly, CTS gives distinctive worth by means of casual but impactful hallway conversations. These interactions present a uncommon alternative to community, reconnect with colleagues and meet new friends who share a dedication to advancing retina analysis.
For extra info:
Arshad M. Khanani, MD, MA, FASRS, of Sierra Eye Associates in Reno, Nevada, may be reached at arshad.khanani@gmail.com.
Assembly info may be discovered at https://www.ctsretina.org/.
Sources/Disclosures
Collapse
Healio Interviews
Disclosures:
Khanani reviews being co-chair and founding father of Scientific Trials on the Summit.
